Eli Lilly beats profit estimates on diabetes and weight-loss drug strength
Eli Lilly beat Wall Street estimates for first-quarter profit on Tuesday, helped by rising demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. The...